Latest News

All Articles

Filter by:
Topic
Acute Myeloid Leukemia under microscope
Drug Updates

Pharmacist's Application to Practice: Quizartinib

November 06, 2023

Eugene Lee, BS, PharmD, Medical Affairs Postdoctoral Fellow, UNC/GSK and Amber Cipriani, PharmD, BCOP, Precision Medicine Pharmacy Coordinator at UNC Health Medical Center write about Quizartinib.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Elranatamab-bcmm

November 06, 2023

Emily Lo, PharmD Candidate and Chung-Shien Lee, PharmD, BCPS, BCOP at St John’s University College of Pharmacy and Health Sciences write about Elranatamab-bcmm).

Advocacy

HOPA Supports Pharmacists, Hopes for Workplace Conditions that Optimize Patient Care

October 25, 2023

The pharmacy profession is experiencing unprecedented rates of burnout and good-faith and timely talks are key to swift and satisfactory workforce negotiations.

Journal Club

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

October 23, 2023

Amivantamab–chemotherapy improved PFS and intracranial PFS versus chemotherapy.

HOPA News

3 FEATURE Indication Withdrawals of Small Molecule Inhibitors from the Accelerated Approval Program

October 18, 2023

The United States Food and Drug Administration’s (FDA) Accelerated Approval Program, which expedites approval of drugs and biologics that treat serious conditions such as cancer, has drawn criticism for allowing products to reach the market only to see th

V600 Mutations
Journal Club

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations

September 21, 2023

Detection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy.

Collaborations

HOPA Partners with Pharmacy Quality Alliance to Improve Cancer Care Quality

August 23, 2023

Three HOPA members were among the 23 national experts and patients convened by PQA to improve the quality of care for individuals using oral anticancer medications.

Multiple Myeloma
Journal Club

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

August 15, 2023

Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy.

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Talquetamab-tgvs

August 09, 2023

Marguerite Courtney, PharmD Candidate 2024 and Bradley Yelvington, PharmD, BCOP from University of Tennessee discuss talquetamab-tgvs

Refractory Multiple Myeloma
Journal Club

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

July 27, 2023

In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician’s choice of effective standard care.

Conference Image
Education

2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

July 26, 2023

The in-person annual Transplantation & Cellular Therapy Meetings of ASTCT™ (American Society for Transplantation and Cellular Therapy) and CIBMTR® (Center for International Blood and Marrow Transplant Research) took place from February 15-19, 2023 in Orla

prostate cancer
Journal Club

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

July 22, 2023

Talazoparib plus enzalutamide resulted in clinically meaningful and statistically significant improvement in rPFS versus standard of care enzalutamide as first-line treatment for patients with mCRPC.